Alcon
Alcon's revenue rose 4.9% to $10.4 billion in fiscal 2025. Its operating margin was 13.1%, down from 14.3% a year earlier. Free cash flow was $1.7 billion, up 7.7%. It paid out $842 million in dividends and buybacks, 49% of free cash flow. The diluted share count fell 0.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Revenue and margins
Net income and earnings per share
From fiscal 2010 to 2025, earnings per share fell 8.3% a year and net income 5.3% a year, as new shares raised the share count by 63% and diluted each share's earnings.
Returns on capital
Cash flow
Payouts and share count
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1,578 | 980 | 1,094 | 1,676 | 1,527 |
| Debt incl. finance leases | 4,080 | 4,648 | 4,739 | 4,643 | 4,737 |
| Net debt (negative means net cash) | 2,502 | 3,668 | 3,645 | 2,967 | 3,210 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.2x | 0.2x | 0.2x | 0.2x | 0.2x |
| Interest coverage | 4.8x | 5.0x | 5.5x | 7.4x | 6.7x |
| Current ratio | 2.2x | 1.9x | 2.4x | 2.8x | 2.1x |
| Quick ratio | 1.4x | 1.1x | 1.4x | 1.8x | 1.3x |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 8 of 9 | 8 of 9 | 6 of 9 |
| Accruals ratio | −1.4% | −3.5% | −4.2% |
Compare
Put Alcon side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Alcon | FY25 | 4.9% | 13.1% | 16.6% | 4.6% | — | 6 | |
| Cooper Companies | FY25 | 5.1% | 16.7% | 10.6% | 4.3% | 2.3x | 5 | Compare |
| Align Technology | FY25 | 0.9% | 13.5% | 12.2% | 13.3% | −1.4x | 5 | Compare |
| Dentsply Sirona | FY25 | −3.0% | −11.5% | 2.8% | −9.9% | — | 6 | Compare |
| West Pharmaceutical Services | FY25 | 6.2% | 19.0% | 15.2% | 18.7% | −0.8x | 9 | Compare |
10 years of figures
| Fiscal year | FY10 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 7,179 | 6,792 | 7,153 | 7,508 | 6,833 | 8,291 | 8,717 | 9,455 | 9,911 | 10,401 |
| Revenue growth | 10.5% | — | 5.3% | 5.0% | −9.0% | 21.3% | 5.1% | 8.5% | 4.8% | 4.9% |
| Gross profit | 5,504 | 3,204 | 3,192 | 3,662 | 2,940 | 4,652 | 4,748 | 5,247 | 5,512 | 5,745 |
| Research and development | 747 | 584 | 587 | 656 | 673 | 842 | 702 | 828 | 876 | 990 |
| Operating income | 2,475 | −77 | −248 | −187 | −482 | 580 | 672 | 1,039 | 1,413 | 1,360 |
| Net income | 2,210 | 256 | −227 | −656 | −531 | 376 | 335 | 974 | 1,018 | 980 |
| Diluted EPS (US$) | 7.27 | 0.52 | −0.46 | −1.34 | −1.09 | 0.76 | 0.68 | 1.96 | 2.05 | 1.98 |
| Diluted shares (millions) | 304 | 488 | 488 | 488 | 489 | 493 | 494 | 496 | 498 | 496 |
| Cash flow | ||||||||||
| Cash from operations | 2,375 | 1,218 | 1,140 | 920 | 823 | 1,345 | 1,217 | 1,388 | 2,077 | 2,271 |
| Capital expenditure | 309 | 415 | 524 | 553 | 479 | 700 | 636 | 658 | 473 | 543 |
| Free cash flow | 2,066 | 803 | 616 | 367 | 344 | 645 | 581 | 730 | 1,604 | 1,728 |
| Dividends paid | 1,037 | 0 | 0 | 0 | 0 | 54 | 100 | 116 | 130 | 166 |
| Share buybacks | 33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 676 |
| Acquisitions | 529 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 78 | 71 | 93 | 114 | 113 | 151 | 152 | 159 | 162 | 171 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 3,414 | — | 227 | 822 | 1,557 | 1,578 | 980 | 1,094 | 1,676 | 1,527 |
| Debt incl. finance leases | 399 | — | 47 | 3,479 | 4,118 | 4,080 | 4,648 | 4,739 | 4,643 | 4,737 |
| Total assets | 10,073 | — | 27,062 | 27,655 | 27,600 | 27,999 | 29,165 | 29,614 | 30,347 | 31,555 |
| Total liabilities | 2,821 | — | 4,423 | 8,352 | 8,778 | 8,743 | 9,488 | 8,990 | 8,794 | 9,520 |
| Shareholders' equity | 7,252 | 23,029 | 22,639 | 19,303 | 18,822 | 19,256 | 19,677 | 20,624 | 21,553 | 22,034 |
| Margins and ratios | ||||||||||
| Gross margin | 76.7% | 47.2% | 44.6% | 48.8% | 43.0% | 56.1% | 54.5% | 55.5% | 55.6% | 55.2% |
| Operating margin | 34.5% | −1.1% | −3.5% | −2.5% | −7.0% | 7.0% | 7.7% | 11.0% | 14.3% | 13.1% |
| Net margin | 30.8% | 3.8% | −3.2% | −8.7% | −7.8% | 4.5% | 3.8% | 10.3% | 10.3% | 9.4% |
| Free cash flow margin | 28.8% | 11.8% | 8.6% | 4.9% | 5.0% | 7.8% | 6.7% | 7.7% | 16.2% | 16.6% |
| Return on capital | 59.1% | — | — | −0.7% | −1.8% | 2.4% | 2.2% | 4.4% | 4.7% | 4.6% |
| Return on equity | 33.6% | — | — | −3.1% | −2.8% | 2.0% | 1.7% | 4.8% | 4.8% | 4.5% |
| Return on assets | 23.6% | — | — | −2.4% | −1.9% | 1.4% | 1.2% | 3.3% | 3.4% | 3.2% |
| Net debt to EBITDA | −1.1x | — | — | — | — | — | — | — | — | — |